BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag

BIOLARGO, INC.

Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.
Cellinity battery signed four MOUs with JV partners; each factory >$100M build, $500M annual revenue capacity; targets enterprise value >$2B.
First paid PFAS treatment project in New Jersey underway; AEC removes PFAS below 4 ppt; CEO named to U.S. Dept of Commerce ETTAC.
ONM (Pooph) sales decline led to increased AR, lower cash, downward stock pressure; payback arrangement and new Pooph ads launched.
BLEST engineering revenues grew 152% YoY in Q1 2025; potential multimillion-dollar projects in pipeline.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.